Rinvoq (Upadacitinib) Denied by Insurance

Rinvoq (upadacitinib) is an oral JAK inhibitor (Janus kinase inhibitor) developed by AbbVie, approved by the FDA for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, and Crohn's disease. Its oral formulation is a significant advantage over injectable biologics for many patients. However, Rinvoq faces a unique layer of insurance denial risk that other biologics do not: FDA black box warnings tied to the entire JAK inhibitor drug class that have led many insurers to restrict coverage more aggressively than clinical evidence alone would justify.

Why Insurance Denies Rinvoq

JAK inhibitor black box warnings are the most significant and unique barrier. Following a 2021 FDA safety communication based on the ORAL Surveillance trial of tofacitinib (Xeljanz), the FDA required all JAK inhibitors — including Rinvoq — to carry a class-wide black box warning about the risk of serious infections, malignancy, major cardiovascular events (MACE), thrombosis, and death. These warnings prompted many insurers to restrict JAK inhibitors to patients who have failed one or more TNF inhibitors, arguing that the risk profile warrants reserving JAK inhibitors as later-line agents. This is despite the fact that Rinvoq is not the drug that generated the ORAL Surveillance data, and that its own clinical trial data shows a different risk profile.

Step therapy is extremely strict for JAK inhibitors. Because of the black box warnings, many commercial and Medicare plans require patients to have tried and failed at least one — and sometimes two — TNF inhibitors before approving Rinvoq, even for indications where clinical guidelines support earlier use.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization is required and is more intensive than for standard biologics due to the FDA safety requirements. PA criteria typically include: diagnosis confirmation, active disease severity documentation, prior TNF inhibitor failure, cardiovascular risk assessment, absence of active malignancy, and thrombosis risk evaluation.

REMS program considerations exist for Rinvoq as part of the class-wide JAK inhibitor REMS (Risk Evaluation and Mitigation Strategy) that the FDA has implemented. While the REMS does not prevent prescribing, it requires prescriber and patient enrollment in a registry and documentation of informed consent regarding the black box risks.

Atopic dermatitis patients face additional barriers because Rinvoq for eczema represents a newer use of JAK inhibitors in a non-rheumatologic condition. Some insurers have been slower to update their eczema coverage policies to include oral JAK inhibitors like Rinvoq, or require more extensive prior topical and biologic failure.

How to Appeal a Rinvoq Denial

Challenge the class-wide black box restriction as applied to your case. The ORAL Surveillance trial was conducted in older RA patients with cardiovascular risk factors on tofacitinib — not upadacitinib, and not necessarily in patients who match your profile. If you are younger, have low cardiovascular risk, no malignancy history, and no thrombosis risk factors, your physician should document this explicitly and argue that the blanket restriction is not clinically appropriate for your individual risk-benefit profile.

Document prior TNF inhibitor failure. If step therapy is the basis of denial, provide detailed records of every TNF inhibitor you tried — dates, doses, duration, response, and reason for failure. If TNF inhibitors were contraindicated for you (due to demyelinating disease, prior lymphoma, or other reasons), document the contraindication explicitly.

Provide active disease severity evidence. For RA, include DAS28 or CDAI scores. For atopic dermatitis, EASI and SCORAD scores. For UC and Crohn's, Mayo Clinic Score and CDAI/Harvey-Bradshaw index. For spondyloarthritis, BASDAI and ASDAS scores. Objective severity documentation is essential.

Address the risk-benefit analysis. Your rheumatologist or dermatologist should include a statement in the medical necessity letter that they have discussed the risks disclosed in the FDA black box warning with you, that you and your physician believe the clinical benefits outweigh the risks for your specific case, and that the monitoring plan is appropriate.

Pursue peer-to-peer review and external appeal. JAK inhibitor denials based on class restrictions rather than individual clinical assessment are often overturned in External Independent Review: Complete Guide" class="auto-link">external review, particularly when the patient's risk profile does not match the high-risk population studied in ORAL Surveillance.

Patient Assistance Programs

AbbVie offers RinvoqComplete, a patient support program providing copay assistance for commercially insured patients and free drug for qualifying uninsured or underinsured patients. Contact RinvoqComplete at 1-800-2RINVOQ or visit rinvoq.com/support.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?